Neuropace (NPCE)

• Market cap: $312M
• 1 day: -6.39%
• 5 days: -7.75%
• 1 month: -19.53%
• 3 months: -8.64%
• 6 months: -21.39%
• Year to date: -17.79%
• 1 year: 28.48%
• 5 years: -61.86%
• 10 years: -61.86%
• Sector: Healthcare
• Industry: Medical Devices

About: NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.

Employees: 195

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

483% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 6

340% more call options, than puts

Call options by funds: $22K | Put options by funds: $5K

107% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 14

45% more funds holding

Funds holding: 62 [Q4 2024] → 90 (+28) [Q1 2025]

26% more capital invested

Capital invested by funds: $234M [Q4 2024] → $294M (+$60.6M) [Q1 2025]

3.59% more ownership

Funds ownership: 69.91% [Q4 2024] → 73.5% (+3.59%) [Q1 2025]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $16 68% upside
• Avg. target: $17 79% upside
• High target: $18 89% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Yi Chen	89% upside $18	Buy Initiated	28 May 2025
JP Morgan Robbie Marcus	68% upside $16	Overweight Maintained	14 May 2025
Cantor Fitzgerald Ross Osborn	79% upside $17	Overweight Reiterated	14 May 2025